<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02915965</url>
  </required_header>
  <id_info>
    <org_study_id>ESCC01-SUMS6</org_study_id>
    <nct_id>NCT02915965</nct_id>
  </id_info>
  <brief_title>A Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Phase II Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether docetaxel, cisplatin, and capecitabine
      (DCX) are effective as the neoadjuvant chemotherapy before esophagectomy in patients with
      loco-regional esophageal squamous cell carcinoma (ESCC).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic response rate</measure>
    <time_frame>2 years</time_frame>
    <description>Pathologic response rate is defined as tumor regression score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse event based on CTCAE 4.0</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of adverse event in patients during treatment period graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Stage II and III Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>DCX and surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxol 60mg/m2 iv d1 and cisplatin 30mg/m2 iv d1-2 and capecitabine 850mg/m2 bid po d1-14 repeated every 21 days for 4-6 cycles, followed by surgery of Ivor Lewis Esophagectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCX</intervention_name>
    <description>docetaxel, cisplatin and capecitabine</description>
    <arm_group_label>DCX and surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>Ivor Lewis Esophagectomy</description>
    <arm_group_label>DCX and surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologic diagnosis of squamous cell thoracic esophageal carcinoma of Stage II or
             III, which is potentially resectable.

          2. Patients must not have received any prior anticancer therapy.

          3. More than 6 months of expected survival.

          4. Age ranges from 18 to 70 years.

          5. Absolute white blood cells count ≥4.0×109/L, neutrophil ≥1.5×109/L, platelets
             ≥100.0×109/L, hemoglobin ≥90g/L, and normal functions of liver and kidney.

          6. Karnofsky performance status (KPS) of 90 or more.

          7. Signed informed consent document on file.

        Exclusion Criteria:

          1. Patients are diagnosed or suspected to be allergic to docetaxol or cisplatin or
             capecitabine.

          2. Patients with concomitant hemorrhagic disease.

          3. Pregnant or breast feeding.

          4. Inability to use gastric conduit after esophagectomy because of a prior surgery.

          5. Patients with concomitant peripheral neuropathy, whose common toxicity criterion (CTC)
             status is 2 or even more.

          6. Have a prior malignancy other than esophageal carcinoma, carcinoma in situ of the
             cervix, nonmelanoma skin cancer or cured early stage of prostate cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhong Deng, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanhong Deng, MD PHD</last_name>
    <phone>+86020 38379762</phone>
    <email>dengyanh@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiayu Ling, MD</last_name>
    <phone>+86020 38379762</phone>
    <email>lingjiay@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2016</study_first_submitted>
  <study_first_submitted_qc>September 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>September 24, 2016</last_update_submitted>
  <last_update_submitted_qc>September 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yanhong Deng</investigator_full_name>
    <investigator_title>MD, PHD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

